Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies

Despite pleas of breast cancer advocates to maintain access to Avastin using gene markers to identify those most likely to benefit, there is little evidence to suggest that the drug company or regulatory experts are considering this strategy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.